Hyperparathyroidism differential diagnosis: Difference between revisions
m Bot: Removing from Primary care |
|||
(27 intermediate revisions by 5 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
[[Image:Home_logo1.png|right|250px|link=https://www.wikidoc.org/index.php/Hyperparathyroidism]] | |||
{{ | |||
{{CMG}};{{AE}}{{Anmol}} | |||
==Overview== | ==Overview== | ||
There are three types of hyperparathyroidism and should be differentiated between each other. Hyperparathyroidism should be | There are three types of hyperparathyroidism (primary, secondary, and tertiary) and should be differentiated between each other. Hyperparathyroidism should be differentiated from other causes of [[hypercalcemia]]. Causes of [[hypercalcemia]] other than hyperparathyroidism include [[familial hypocalciuric hypercalcemia]], [[hypercalcemia]] related to [[malignancy]], [[medication-induced]] [[hypercalcemia]], [[hypercalcemia]] due to [[nutritional]] disorders, and [[hypercalcemia]] related to [[Granulomatous|granulomatous diseases]]. | ||
==Differentiating hyperparathyroidism from other diseases== | ==Differentiating hyperparathyroidism from other diseases== | ||
There are three types of hyperparathyroidism and should be differentiated between each other. | There are three types of hyperparathyroidism (primary, secondary, and tertiary) and should be differentiated between each other. Hyperparathyroidism should be differentiated from other causes of [[hypercalcemia]]. Causes of [[hypercalcemia]] include: | ||
Hyperparathyroidism should be differentiated from other causes of hypercalcemia. Causes of hypercalcemia include: | *'''Parathyroid related''' | ||
*Parathyroid related | |||
**Hyperparathyroidism | **Hyperparathyroidism | ||
***Primary hyperparathyroidism | ***Primary hyperparathyroidism | ||
***Secondary hyperparathyroidism | ***Secondary hyperparathyroidism | ||
***Tertiary hyperparathyroidism | ***Tertiary hyperparathyroidism | ||
**Familial hypocalciuric hypercalcemia | **[[Familial hypocalciuric hypercalcemia]] | ||
*Non-parathyroid related | *'''Non-parathyroid related''' | ||
**Malignancy | **[[Malignancy]] | ||
***Humoral hypercalcemia of malignancy | ***Humoral [[hypercalcemia]] of [[malignancy]] | ||
***Osteolytic tumors | ***[[Osteolytic metasteses|Osteolytic tumors]] | ||
***Production of calcitriol by tumors | ***Production of [[calcitriol]] by [[Tumor|tumors]] | ||
***Ectopic parathyroid hormone production | ***[[Ectopia|Ectopic]] [[parathyroid hormone]] production | ||
**Medication induced | **[[Medication-induced]] | ||
***Thiazide diuretics | ***[[Thiazide diuretics]] | ||
***Lithium | ***[[Lithium]] | ||
**Nutritional | **[[Nutritional]] | ||
***Milk alkali syndrome | ***[[Milk-alkali syndrome]] | ||
***Vitamin D toxicity | ***[[Hypervitaminosis D|Vitamin D toxicity]] | ||
**Granulomatous disease | **[[Granulomatous]] disease | ||
***Sarcoidosis | ***[[Sarcoidosis]] | ||
**Surgical | **Surgical | ||
*** | ***Immobization | ||
<br> | |||
{| | {| | ||
! colspan=" | ! colspan="9" style="background: #4479BA; text-align: center;" |{{fontcolor|#FFF|Differential diagnosis of hyperparathyroidism on the basis of hypercalcemia}} | ||
|- | |- | ||
! colspan="2" style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Disorder}} | ! colspan="2" rowspan="2" style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Disorder}} | ||
! style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Mechanism of hypercalcemia}} | ! rowspan="2" style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Mechanism of hypercalcemia}} | ||
! style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Clinical features}} | ! rowspan="2" style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Clinical features}} | ||
! style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Laboratory findings}} | ! colspan="4" style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Laboratory findings}} | ||
! style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Imaging & diagnostic modalities}} | ! rowspan="2" style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Imaging & diagnostic modalities}} | ||
|- | |- | ||
| rowspan="3" style="background: # | ! style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|PTH}} | ||
! style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Calcium}} | |||
| style="background: # | ! style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Phosphate}} | ||
| style="background: # | ! style="background: #7d7d7d; text-align: center;" |{{fontcolor|#FFF|Other findings}} | ||
|- | |||
! rowspan="3" style="background: #DCDCDC; text-align: center;" |'''Hyperparathyroidism''' | |||
! style="background: #DCDCDC; text-align: center;" |Primary hyperparathyroidism | |||
| style="background: #F5F5F5;" |Increase in [[secretion]] of [[parathyroid hormone]] ([[PTH]]) from a primary process in [[parathyroid gland]]. [[Parathyroid hormone]] causes increase in [[serum]] [[calcium]]. | |||
| style="background: #F5F5F5;" | | |||
* Usually asymptomatic | * Usually asymptomatic | ||
* Hypercalcemia detected on routine biochemical panel | * [[Hypercalcemia]] detected on routine biochemical panel | ||
| style="background: # | | style="background: #F5F5F5; text-align: center;" |↑ | ||
| style="background: #F5F5F5; text-align: center;" |↑ | |||
| style="background: #F5F5F5; text-align: center;" |↓/Normal | |||
| style="background: #F5F5F5; text-align: center;" |Normal/↑ calcitriol | |||
| rowspan="3" style="background: #F5F5F5;" |Findings of bone resorption: | |||
| rowspan="3" style="background: # | * [[X-ray]] | ||
* X-ray | * [[Dual energy X-ray absorptiometry]] ([[DXA]]) | ||
* DXA | Preoperative localization of hyperfunctioning [[parathyroid gland]]: | ||
Preoperative localization of hyperfunctioning parathyroid gland: | |||
* Non-Invasive | * Non-Invasive | ||
** Tc-99m sestamibi scintigraphy | ** [[Tc-99m sestamibi scintigraphy]] | ||
** Neck ultrasound | ** Neck [[ultrasound]] | ||
** 4D-CT | ** 4D-CT | ||
** | ** [[SPECT]](P-SPECT) | ||
** PET | ** [[Positron emission tomography|PET]] | ||
** MRI | ** [[MRI]] | ||
* Invasive: | * Invasive: | ||
** Super sensitive venous sampling | ** Super sensitive [[venous]] sampling | ||
** Selective arteriography | ** Selective [[arteriography]] | ||
** Angiography | ** [[Angiogram|Angiography]] | ||
Predicting post-operative success: | Predicting post-operative success: | ||
* Intraoperative parathyroid hormone monitoring | * [[Intraoperative parathyroid hormone]] monitoring | ||
|- | |- | ||
! style="background: #DCDCDC; text-align: center;" |Secondary hyperparathyroidism | |||
| style="background: # | | style="background: #F5F5F5;" |Increase in [[secretion]] of [[parathyroid hormone]] ([[PTH]]) from a secondary process. [[Parathyroid hormone]] causes increase in [[serum]] [[calcium]] after long periods. | ||
| style="background: # | | style="background: #F5F5F5;" | | ||
* May present with history of: | * May present with history of: | ||
** Chronic renal failure | ** [[Chronic renal failure]] | ||
** Vitamin D deficiency | ** [[Vitamin D deficiency]] | ||
| style="background: # | | style="background: #F5F5F5; text-align: center;" |↑ | ||
| style="background: #F5F5F5; text-align: center;" |↓/Normal | |||
| style="background: #F5F5F5; text-align: center;" |↑ | |||
| style="background: #F5F5F5; text-align: center;" | -- | |||
|- | |- | ||
! style="background: #DCDCDC; text-align: center;" |Tertiary hyperparathyroidism | |||
| style="background: # | | style="background: #F5F5F5;" |Continuous elevation of [[parathyroid hormone]] (PTH) even after successful treatment of the secondary cause of elevated [[parathyroid hormone]]. [[Parathyroid hormone]] causes increase in serum calcium. | ||
| style="background: # | | style="background: #F5F5F5;" | | ||
* Usually present with history of | * Usually present with history of [[kidney transplant]] | ||
* Usually [[hyperplasia]] of all four [[parathyroid glands]] | |||
* Usually hyperplasia of all four parathyroid glands | | style="background: #F5F5F5; text-align: center;" |↑ | ||
| style="background: # | | style="background: #F5F5F5; text-align: center;" |↑ | ||
| style="background: #F5F5F5; text-align: center;" |↑ | |||
| style="background: #F5F5F5; text-align: center;" | -- | |||
|- | |- | ||
! colspan="2" style="background: #DCDCDC; text-align: center;" |[[Familial hypocalciuric hypercalcemia]] | |||
| style="background: # | | style="background: #F5F5F5;" |This is a [[genetic disorder]] caused my [[mutation]] in [[calcium-sensing receptor]] gene. | ||
| style="background: #F5F5F5;" | | |||
| style="background: # | * A benign condition | ||
* | * Does not require treatment | ||
| style="background: # | | style="background: #F5F5F5; text-align: center;" |Normal/↑ | ||
| style="background: #F5F5F5; text-align: center;" |Normal/↑ | |||
| style="background: #F5F5F5; text-align: center;" | -- | |||
| style="background: # | | style="background: #F5F5F5; text-align: center;" | -- | ||
* | | style="background: #F5F5F5;" | | ||
* Urinary calcium/creatinine clearance ratio | |||
|- | |- | ||
! rowspan="4" style="background: #DCDCDC; text-align: center;" |'''Malignancy'''<ref name="pmid26713296">{{cite journal |vauthors=Mirrakhimov AE |title=Hypercalcemia of Malignancy: An Update on Pathogenesis and Management |journal=N Am J Med Sci |volume=7 |issue=11 |pages=483–93 |year=2015 |pmid=26713296 |pmc=4683803 |doi=10.4103/1947-2714.170600 |url=}}</ref><ref name="pmid15673803">{{cite journal| author=Stewart AF| title=Clinical practice. Hypercalcemia associated with cancer. | journal=N Engl J Med | year= 2005 | volume= 352 | issue= 4 | pages= 373-9 | pmid=15673803 | doi=10.1056/NEJMcp042806 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15673803 }} </ref> | |||
! style="background: #DCDCDC; text-align: center;" |Humoral hypercalcemia of malignancy<ref name="pmid1346019">{{cite journal |vauthors=Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG |title=Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia |journal=Lancet |volume=339 |issue=8786 |pages=164–7 |year=1992 |pmid=1346019 |doi=10.1016/0140-6736(92)90220-W |url=}}</ref><ref name="pmid7962324">{{cite journal |vauthors=Ikeda K, Ohno H, Hane M, Yokoi H, Okada M, Honma T, Yamada A, Tatsumi Y, Tanaka T, Saitoh T |title=Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma |journal=J. Clin. Endocrinol. Metab. |volume=79 |issue=5 |pages=1322–7 |year=1994 |pmid=7962324 |doi=10.1210/jcem.79.5.7962324 |url=}}</ref><ref name="pmid12679445">{{cite journal |vauthors=Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocaña A, Stewart AF |title=Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers |journal=J. Clin. Endocrinol. Metab. |volume=88 |issue=4 |pages=1603–9 |year=2003 |pmid=12679445 |doi=10.1210/jc.2002-020773 |url=}}</ref><ref name="pmid7085851">{{cite journal| author=Stewart AF, Vignery A, Silverglate A, Ravin ND, LiVolsi V, Broadus AE et al.| title=Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity. | journal=J Clin Endocrinol Metab | year= 1982 | volume= 55 | issue= 2 | pages= 219-27 | pmid=7085851 | doi=10.1210/jcem-55-2-219 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7085851 }} </ref> | |||
| style="background: # | | style="background: #F5F5F5;" |[[Tumor]] cells secretes [[parathyroid hormone-related protein]] ([[PTHrP]]) which has similar action as [[parathyroid hormone]]. | ||
| style="background: # | | style="background: #F5F5F5;" | | ||
* Most common cause of malignancy related hypercalcemia | * Most common cause of [[malignancy]] related [[hypercalcemia]] | ||
* Usually present | * Usually present with [[solid tumors]] | ||
| style="background: # | | style="background: #F5F5F5; text-align: center;" | -- | ||
| style="background: #F5F5F5; text-align: center;" |↑ | |||
| style="background: #F5F5F5; text-align: center;" |↓/Normal | |||
| style="background: #F5F5F5; text-align: center;" |↑ [[PTHrP]] | |||
| style="background: # | Normal/↑ calcitriol | ||
* Chest X-ray | | style="background: #F5F5F5;" | | ||
* CT scan | * [[Chest X-rays|Chest X-ray]] | ||
* MRI | * [[CT scan]] | ||
* [[MRI]] | |||
|- | |- | ||
! style="background: #DCDCDC; text-align: center;" |Osteolytic tumors<ref name="pmid15084698">{{cite journal| author=Roodman GD| title=Mechanisms of bone metastasis. | journal=N Engl J Med | year= 2004 | volume= 350 | issue= 16 | pages= 1655-64 | pmid=15084698 | doi=10.1056/NEJMra030831 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15084698 }} </ref><ref name="pmid8833902">{{cite journal| author=Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF et al.| title=Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. | journal=J Clin Invest | year= 1996 | volume= 98 | issue= 7 | pages= 1544-9 | pmid=8833902 | doi=10.1172/JCI118947 | pmc=507586 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8833902 }} </ref> | |||
| style="background: # | | style="background: #F5F5F5;" |[[Multiple myeloma]] produces [[osteolysis]] of [[bones]] causing [[hypercalcemia]]. [[Osteolytic metasteses]] can cause [[bone resorption]] causing [[hypercalcemia]]. | ||
| style="background: # | | style="background: #F5F5F5;" | | ||
* | * Commonly present in [[multiple myeloma]] and [[breast cancer]] | ||
| style="background: # | | style="background: #F5F5F5; text-align: center;" |↓ | ||
| style="background: #F5F5F5; text-align: center;" |↑ | |||
| style="background: #F5F5F5; text-align: center;" | -- | |||
| style="background: # | | style="background: #F5F5F5; text-align: center;" | -- | ||
* DXA | | style="background: #F5F5F5;" | | ||
* X-ray | * [[DXA]] | ||
* Mammography | * [[X-ray]] | ||
* Ultrasound | * [[Mammography]] | ||
* ESR | * [[Ultrasound]] | ||
* Serum protein electrophoresis | * [[ESR]] | ||
* [[Serum protein electrophoresis]] | |||
|- | |- | ||
! style="background: #DCDCDC; text-align: center;" |Production of calcitirol<ref name="pmid7944070">{{cite journal| author=Seymour JF, Gagel RF, Hagemeister FB, Dimopoulos MA, Cabanillas F| title=Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma. | journal=Ann Intern Med | year= 1994 | volume= 121 | issue= 9 | pages= 633-40 | pmid=7944070 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7944070 }} </ref> | |||
| style="background: # | | style="background: #F5F5F5;" |Some tumors has ectopic activity of 1-alpha-hydroxylase leading to increased production of [[calcitriol]]. [[Calcitriol]] is active form of [[vitamin D]] and causes [[hypercalcemia]]. | ||
| style="background: # | | style="background: #F5F5F5;" | | ||
* | * Commonly present in [[lymphomas]] and in some [[Ovarian cancer|ovarian germ cell tumors]] | ||
| style="background: # | | style="background: #F5F5F5; text-align: center;" | -- | ||
| style="background: #F5F5F5; text-align: center;" |↑ | |||
| style="background: #F5F5F5; text-align: center;" | -- | |||
| style="background: # | | style="background: #F5F5F5; text-align: center;" |↑ [[Calcitriol]] | ||
* CT scan | | style="background: #F5F5F5;" | | ||
* MRI | * [[CT scan]] | ||
* [[MRI]] | |||
|- | |- | ||
! style="background: #DCDCDC; text-align: center;" |Ectopic parathyroid hormone<ref name="pmid16263810">{{cite journal |vauthors=VanHouten JN, Yu N, Rimm D, Dotto J, Arnold A, Wysolmerski JJ, Udelsman R |title=Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene |journal=J. Clin. Endocrinol. Metab. |volume=91 |issue=2 |pages=580–3 |year=2006 |pmid=16263810 |doi=10.1210/jc.2005-2095 |url=}}</ref> | |||
| style="background: # | | style="background: #F5F5F5;" |Some tumors leads to [[Ectopia|ectopic]] production of [[parathyroid hormone]]. | ||
| style="background: # | | style="background: #F5F5F5;" | | ||
* In rare instances, small cell carcinoma of lung may produce hypercalcemia by this process | * In rare instances, [[small cell carcinoma of lung]] may produce [[hypercalcemia]] by this process | ||
| style="background: # | | style="background: #F5F5F5; text-align: center;" |↑ | ||
| style="background: #F5F5F5; text-align: center;" |↑ | |||
| style="background: #F5F5F5; text-align: center;" |↓/Normal | |||
| style="background: #F5F5F5; text-align: center;" |Normal/↑ [[calcitriol]] | |||
| style="background: #F5F5F5;" | | |||
| style="background: # | * [[Chest X-rays|Chest X-ray]] | ||
* Chest X-ray | * [[CT scan]] | ||
* CT scan | * [[MRI]] | ||
* MRI | |||
|- | |- | ||
! rowspan="2" style="background: #DCDCDC; text-align: center;" |'''Medication induced''' | |||
! style="background: #DCDCDC; text-align: center;" |Lithium<ref name="pmid2918061">{{cite journal |vauthors=Mallette LE, Khouri K, Zengotita H, Hollis BW, Malini S |title=Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume |journal=J. Clin. Endocrinol. Metab. |volume=68 |issue=3 |pages=654–60 |year=1989 |pmid=2918061 |doi=10.1210/jcem-68-3-654 |url=}}</ref> | |||
| style="background: # | | style="background: #F5F5F5;" |[[Lithium]] lowers [[Urinary System|urinary]] [[calcium]] and causes [[hypercalcemia]]. [[Lithium]] has been reported to cause an increase in [[parathyroid hormone]] and enlargement if [[parathyroid gland]] after weeks to months of therapy. | ||
| style="background: # | | style="background: #F5F5F5;" | | ||
* History of mood disorder | * History of [[mood disorder]] | ||
| style="background: # | | style="background: #F5F5F5; text-align: center;" |↑ | ||
| style="background: #F5F5F5; text-align: center;" |↑ | |||
| style="background: #F5F5F5; text-align: center;" | -- | |||
| style="background: # | | style="background: #F5F5F5; text-align: center;" | -- | ||
* Lithium levels | | style="background: #F5F5F5;" | | ||
* [[Lithium]] levels | |||
|- | |- | ||
! style="background: #DCDCDC; text-align: center;" |Thiazide diuretics<ref name="pmid26751196">{{cite journal| author=Griebeler ML, Kearns AE, Ryu E, Thapa P, Hathcock MA, Melton LJ et al.| title=Thiazide-Associated Hypercalcemia: Incidence and Association With Primary Hyperparathyroidism Over Two Decades. | journal=J Clin Endocrinol Metab | year= 2016 | volume= 101 | issue= 3 | pages= 1166-73 | pmid=26751196 | doi=10.1210/jc.2015-3964 | pmc=4803175 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26751196 }}</ref> | |||
| style="background: # | | style="background: #F5F5F5;" |[[Thiazide diuretics]] lowers [[urinary]] [[calcium]] [[excretion]] and causes [[hypercalcemia]]. | ||
| style="background: # | | style="background: #F5F5F5;" | | ||
* History of cardiac disorder | * History of [[cardiac]] disorder | ||
* Rarely causes hypercalcemia | * Rarely causes [[hypercalcemia]] | ||
| style="background: # | | style="background: #F5F5F5; text-align: center;" | -- | ||
| style="background: #F5F5F5; text-align: center;" |↑ | |||
| style="background: # | | style="background: #F5F5F5; text-align: center;" | -- | ||
| style="background: #F5F5F5; text-align: center;" | -- | |||
| style="background: #F5F5F5;" | -- | |||
|- | |- | ||
! rowspan="2" style="background: #DCDCDC; text-align: center;" |'''Nutritional''' | |||
! style="background: #DCDCDC; text-align: center;" |Milk-alkali syndrome | |||
| style="background: # | | style="background: #F5F5F5;" |[[Hypercalcemia]] is be caused by high intake of [[calcium carbonate]]. | ||
| style="background: # | | style="background: #F5F5F5;" | | ||
* History of | * History of | ||
** High milk intake | ** High milk intake | ||
** Excess calcium intake for treating: | ** Excess calcium intake for treating: | ||
*** Osteoporosis | *** [[Osteoporosis]] | ||
*** Dyspepsia | *** [[Dyspepsia]] | ||
* May lead to metabolic alkalosis and renal insufficiency. | * May lead to [[metabolic alkalosis]] and [[renal insufficiency]]. | ||
| style="background: # | | style="background: #F5F5F5; text-align: center;" | -- | ||
| style="background: #F5F5F5; text-align: center;" |↑ | |||
| style="background: # | | style="background: #F5F5F5; text-align: center;" | -- | ||
* Renal function | | style="background: #F5F5F5; text-align: center;" |↓ [[calcitriol]] | ||
| style="background: #F5F5F5;" | | |||
* [[Renal function tests]] | |||
|- | |- | ||
! style="background: #DCDCDC; text-align: center;" |Vitamin D toxicity<ref name="pmid81205272">{{cite journal |vauthors=Hoeck HC, Laurberg G, Laurberg P |title=Hypercalcaemic crisis after excessive topical use of a vitamin D derivative |journal=J. Intern. Med. |volume=235 |issue=3 |pages=281–2 |year=1994 |pmid=8120527 |doi= |url=}}</ref><ref name="pmid13135472">{{cite journal |vauthors=Jacobus CH, Holick MF, Shao Q, Chen TC, Holm IA, Kolodny JM, Fuleihan GE, Seely EW |title=Hypervitaminosis D associated with drinking milk |journal=N. Engl. J. Med. |volume=326 |issue=18 |pages=1173–7 |year=1992 |pmid=1313547 |doi=10.1056/NEJM199204303261801 |url=}}</ref><ref name="pmid8620732">{{cite journal| author=Sharma OP| title=Vitamin D, calcium, and sarcoidosis. | journal=Chest | year= 1996 | volume= 109 | issue= 2 | pages= 535-9 | pmid=8620732 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8620732 }}</ref> | |||
| style="background: # | | style="background: #F5F5F5;" |Excess [[vitamin D]] causes increased [[absorption]] of [[calcium]] from [[intestine]] causing [[hypercalcemia]]. | ||
| style="background: # | | style="background: #F5F5F5;" | | ||
* History of: | * History of: | ||
** Excess intake vitamin D | ** Excess intake [[vitamin D]] | ||
** Excess milk fortified with vitamin D<ref name="pmid1313547">{{cite journal |vauthors=Jacobus CH, Holick MF, Shao Q, Chen TC, Holm IA, Kolodny JM, Fuleihan GE, Seely EW |title=Hypervitaminosis D associated with drinking milk |journal=N. Engl. J. Med. |volume=326 |issue=18 |pages=1173–7 |year=1992 |pmid=1313547 |doi=10.1056/NEJM199204303261801 |url=}}</ref> | ** Excess milk fortified with [[vitamin D]]<ref name="pmid1313547">{{cite journal |vauthors=Jacobus CH, Holick MF, Shao Q, Chen TC, Holm IA, Kolodny JM, Fuleihan GE, Seely EW |title=Hypervitaminosis D associated with drinking milk |journal=N. Engl. J. Med. |volume=326 |issue=18 |pages=1173–7 |year=1992 |pmid=1313547 |doi=10.1056/NEJM199204303261801 |url=}}</ref> | ||
** Topical application of vitamin D analogue | ** Topical application of vitamin D analogue [[calcipotriol]]<ref name="pmid8120527">{{cite journal |vauthors=Hoeck HC, Laurberg G, Laurberg P |title=Hypercalcaemic crisis after excessive topical use of a vitamin D derivative |journal=J. Intern. Med. |volume=235 |issue=3 |pages=281–2 |year=1994 |pmid=8120527 |doi= |url=}}</ref> | ||
| style="background: # | | style="background: #F5F5F5; text-align: center;" | -- | ||
| style="background: #F5F5F5; text-align: center;" |↑ | |||
| style="background: #F5F5F5; text-align: center;" | -- | |||
| style="background: # | | style="background: #F5F5F5; text-align: center;" |↑ [[Vitamin D]] ([[calcidiol]] and/or [[calcitriol]]) | ||
| style="background: #F5F5F5;" | -- | |||
|- | |- | ||
! style="background: #DCDCDC; text-align: center;" |'''Granulomatous disease''' | |||
! style="background: #DCDCDC; text-align: center;" |Sarcoidosis<ref name="pmid9215298">{{cite journal |vauthors=Dusso AS, Kamimura S, Gallieni M, Zhong M, Negrea L, Shapiro S, Slatopolsky E |title=gamma-Interferon-induced resistance to 1,25-(OH)2 D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses |journal=J. Clin. Endocrinol. Metab. |volume=82 |issue=7 |pages=2222–32 |year=1997 |pmid=9215298 |doi=10.1210/jcem.82.7.4074 |url=}}</ref> | |||
| style="background: # | | style="background: #F5F5F5;" |[[Hypercalcemia]] is causes by endogeous production of [[calcitriol]] by disease-activated [[Macrophage|macrophages]]. | ||
| style="background: # | | style="background: #F5F5F5;" | | ||
* History of: | * History of: | ||
** Cough | ** [[Cough]] | ||
** Dyspnea | ** [[Dyspnea]] | ||
** Chest pain | ** [[Chest pain]] | ||
** Tiredness or weakness | ** [[Tiredness]] or [[weakness]] | ||
** Fever | ** [[Fever]] | ||
** Weight loss | ** [[Weight loss]] | ||
| style="background: #DCDCDC;" | | | style="background: #F5F5F5; text-align: center;" | -- | ||
* ''' | | style="background: #F5F5F5; text-align: center;" |↑ | ||
* | | style="background: #F5F5F5; text-align: center;" | -- | ||
* | | style="background: #F5F5F5; text-align: center;" |↑ [[Calcitriol]] | ||
| style="background: #DCDCDC;" | | |||
* | ↑ [[ACE]] levels | ||
* | | style="background: #F5F5F5;" | | ||
* [[Chest X-ray]] | |||
* [[Biopsy]] | |||
|} | |||
==DIfferentiating Hyperparathyroidism from other diseases== | |||
<small> | |||
{| style="border: 0px; font-size: 90%; margin: 3px; width: 600px" align="center" | |||
|+ | |||
! rowspan="2" style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Disease}} | |||
! rowspan="2" style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Gene}} | |||
! rowspan="2" style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Chromosome}} | |||
! rowspan="2" style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Differentiating Features}} | |||
! colspan="3" style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Components of MEN}} | |||
! rowspan="2" style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Diagnosis}} | |||
|- | |||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Parathyroid}} | |||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Pitutary}} | |||
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Pancreas}} | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |[[von Hippel-Lindau syndrome]] | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Von Hippel–Lindau tumor suppressor | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |3p25.3 | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
* Angiomatosis, | |||
* Hemangioblastomas, | |||
* Pheochromocytoma, | |||
* Renal cell carcinoma, | |||
* Pancreatic cysts (pancreatic serous cystadenoma) | |||
* Endolymphatic sac tumor, | |||
* Bilateral papillary cystadenomas of the epididymis (men) or broad ligament of the uterus (women) | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |<nowiki>-</nowiki> | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |<nowiki>-</nowiki> | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | + | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
* Clinical diagnosis | |||
* In hereditary VHL, disease techniques such as Southern blotting and gene sequencing can be used to analyse DNA and identify mutations. | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |[[Carney complex]] | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | PRKAR1A | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | 17q23-q24 | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
* Myxomas of the heart | |||
* Hyperpigmentation of the skin (lentiginosis) | |||
* Endocrine (ACTH-independent Cushing's syndrome due to primary pigmented nodular adrenocortical disease) | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
* Clinical diagnosis | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |[[Neurofibromatosis type 1]] | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |RAS | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |17 | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
* [[Scoliosis]] | |||
* Learning disabilities | |||
* [[Vision]] disorders | |||
* Cutaneous [[lesion]]s | |||
* [[Epilepsy]]. | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |'''<u>Prenatal</u>''' | |||
* Chorionic villus sampling or amniocentesis can be used to detect NF-1 in the fetus. | |||
'''<u>Postnatal</u>''' | |||
Cardinal Clinical Features" are required for positive diagnosis. | |||
* Six or more café-au-lait spots over 5 mm in greatest diameter in pre-pubertal individuals and over 15 mm in greatest diameter in post-pubertal individuals. | |||
* Two or more neurofibromas of any type or 1 plexiform neurofibroma | |||
* Freckling in the axillary (Crowe sign) or inguinal regions | |||
* Optic glioma | |||
* Two or more Lisch nodules (pigmented iris hamartomas) | |||
* A distinctive osseous lesion such as sphenoid dysplasia, or thinning of the long bone cortex with or without pseudarthrosis. | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |[[Li-Fraumeni syndrome]] | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |TP53 | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |17 | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Early onset of diverse amount of [[cancer]]s such as | |||
* [[Sarcoma]] | |||
* [[Cancer]]s of | |||
** [[Breast]] | |||
** [[Brain]] | |||
** [[Adrenal gland]]s | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
'''<u>Criteria</u>''' | |||
* Sarcoma at a young age (below 45) | |||
* A first-degree relative diagnosed with any cancer at a young age (below 45) | |||
* A first or second degree relative with any cancer diagnosed before age 60. | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |[[Gardner's syndrome]] | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | APC | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | 5q21 | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
* Multiple polyps in the colon | |||
* Osteomas of the skull | |||
* Thyroid cancer, | |||
* Epidermoid cysts, | |||
* Fibromas | |||
* Desmoid tumors | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
* Clinical diagnosis | |||
* Colonoscopy | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |[[Multiple endocrine neoplasia type 2]] | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |''RET'' | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
* [[Medullary thyroid carcinoma]] (MTC) | |||
* [[Pheochromocytoma]] | |||
* Primary [[hyperparathyroidism]] | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | + | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
* [[Hypercalcemia]] | |||
* [[Hypophosphatemia]], | |||
* Elevated [[parathyroid hormone]], | |||
* Elevated [[norepinephrine]] | |||
'''<u>Criteria</u>''' | |||
Two or more specific endocrine tumors | |||
* [[Medullary thyroid carcinoma]] | |||
* [[Pheochromocytoma]] | |||
* [[Parathyroid]] hyperplasia | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |[[Cowden syndrome]] | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |PTEN | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | Hamartomas | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |<nowiki>-</nowiki> | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
* ''PTEN'' mutation probability risk calculator | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |[[Acromegaly]]/[[gigantism]] | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
* Enlargement of the [[hand]]s, [[feet]], [[nose]], [[lip]]s and [[ear]]s, and a general thickening of the [[skin]] | |||
* [[Hypertrichosis]] | |||
* [[Hyperpigmentation]] | |||
* [[Hyperhidrosis]] | |||
* [[Carpal tunnel syndrome]]. | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |<nowiki>-</nowiki> | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |<nowiki>+</nowiki> | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |<nowiki>-</nowiki> | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
* An elevated concentration of serum [[Growth hormone|growth hormone (GH)]] and [[Insulin-like growth factor|insulin-like growth factor 1(IGF-1)]] levels is diagnostic of acromegaly. | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |[[Pituitary adenoma]] | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
* [[Visual field defect]]s classically [[bitemporal hemianopsia]] | |||
* Increased [[intracranial pressure]] | |||
* [[Migraine]] | |||
* [[Lateral rectus]] palsy | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |<nowiki>+</nowiki> | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
:*Elevated serum level of [[prolactin]] | |||
:*Elevated or decreased serum level of [[adrenocorticotropic hormone]] (ACTH) | |||
:*Elevated or decreased serum level of [[growth hormone]] (GH) | |||
:*Elevated or decreased serum level of [[thyroid-stimulating hormone]] (TSH) | |||
:*Elevated or decreased serum level of [[follicle-stimulating hormone]] (FSH) | |||
:*Elevated or decreased serum level of [[luteinizing hormone]] (LH) | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |[[Hyperparathyroidism]] | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
* [[Kidney stone]]s | |||
* [[Hypercalcemia]], | |||
* [[Constipation]] | |||
* [[Peptic ulcer]]s | |||
* [[Depression]] | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |<nowiki>+</nowiki> | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |<nowiki>-</nowiki> | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |<nowiki>-</nowiki> | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
* An elevated concentration of serum [[calcium]] with elevated [[parathyroid hormone]] level is diagnostic of primary hyperparathyroidism. | |||
* Most consistent laboratory findings associated with the diagnosis of secondary hyperparathyroidism include elevated serum [[parathyroid hormone]] level and low to normal serum [[calcium]]. | |||
* An elevated concentration of serum [[calcium]] with elevated [[parathyroid hormone]] level in post [[Kidney transplantation|renal transplant]] patients is diagnostic of tertiary hyperparathyoidism. | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |[[Pheochromocytoma]]/[[paraganglioma]] | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
''VHL'' | |||
''RET'' | |||
''NF1'' | |||
''SDHB'' | |||
''SDHD'' | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | - | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |Characterized by | |||
* Episodic [[hypertension]] | |||
* [[Palpitation]]s | |||
* [[Anxiety]] | |||
* [[Diaphoresis]] | |||
* [[Weight loss]] | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |<nowiki>-</nowiki> | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |<nowiki>-</nowiki> | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |<nowiki>-</nowiki> | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
* Increased catecholamines and metanephrines in plasma (blood) or through a 24-hour urine collection. | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |[[Adrenocortical carcinoma]] | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
*p53 | |||
*Retinoblastoma h19 | |||
*Insulin-like growth factor II (IGF-II) | |||
*p57<sup>kip2</sup> | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |17p, 13q | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
* [[Cushing syndrome]] ([[cortisol]] hypersecretion) | |||
* [[Conn syndrome]] ([[aldosterone]] hypersecretion) | |||
* [[virilization]] ([[testosterone]] hypersecretion) | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |<nowiki>-</nowiki> | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |<nowiki>-</nowiki> | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" |<nowiki>-</nowiki> | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
* Increased serum glucose | |||
* Increased urine cortisol | |||
* Serum androstenedione and dehydroepiandrosterone | |||
* Low serum potassium | |||
* Low plasma renin activity | |||
* High serum aldosterone. | |||
* Excess serum estrogen. | |||
|- | |||
| colspan="8" style="padding: 5px 5px; background: #F5F5F5;" |<small>Adapted from Toledo SP, Lourenço DM, Toledo RA. A differential diagnosis of inherited endocrine tumors and their tumor counterparts, journal=Clinics (Sao Paulo), volume= 68, issue= 7, 07/24/2013<ref name="pmid23917672">{{cite journal| author=Toledo SP, Lourenço DM, Toledo RA| title=A differential diagnosis of inherited endocrine tumors and their tumor counterparts. | journal=Clinics (Sao Paulo) | year= 2013 | volume= 68 | issue= 7 | pages= 1039-56 | pmid=23917672 | doi=10.6061/clinics/2013(07)24 | pmc=PMC3715026 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23917672 }} </ref> </small> | |||
|} | |} | ||
</small> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category: | | ||
[[Category:Disease]] | |||
[[Category:Medicine]] | |||
[[Category:Endocrinology]] | |||
[[Category:Parathyroid disorders]] | [[Category:Parathyroid disorders]] | ||
[[Category: | [[Category:Up-To-Date]] |
Latest revision as of 22:16, 29 July 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Anmol Pitliya, M.B.B.S. M.D.[2]
Overview
There are three types of hyperparathyroidism (primary, secondary, and tertiary) and should be differentiated between each other. Hyperparathyroidism should be differentiated from other causes of hypercalcemia. Causes of hypercalcemia other than hyperparathyroidism include familial hypocalciuric hypercalcemia, hypercalcemia related to malignancy, medication-induced hypercalcemia, hypercalcemia due to nutritional disorders, and hypercalcemia related to granulomatous diseases.
Differentiating hyperparathyroidism from other diseases
There are three types of hyperparathyroidism (primary, secondary, and tertiary) and should be differentiated between each other. Hyperparathyroidism should be differentiated from other causes of hypercalcemia. Causes of hypercalcemia include:
- Parathyroid related
- Hyperparathyroidism
- Primary hyperparathyroidism
- Secondary hyperparathyroidism
- Tertiary hyperparathyroidism
- Familial hypocalciuric hypercalcemia
- Hyperparathyroidism
- Non-parathyroid related
- Malignancy
- Humoral hypercalcemia of malignancy
- Osteolytic tumors
- Production of calcitriol by tumors
- Ectopic parathyroid hormone production
- Medication-induced
- Nutritional
- Granulomatous disease
- Surgical
- Immobization
- Malignancy
Differential diagnosis of hyperparathyroidism on the basis of hypercalcemia | ||||||||
---|---|---|---|---|---|---|---|---|
Disorder | Mechanism of hypercalcemia | Clinical features | Laboratory findings | Imaging & diagnostic modalities | ||||
PTH | Calcium | Phosphate | Other findings | |||||
Hyperparathyroidism | Primary hyperparathyroidism | Increase in secretion of parathyroid hormone (PTH) from a primary process in parathyroid gland. Parathyroid hormone causes increase in serum calcium. |
|
↑ | ↑ | ↓/Normal | Normal/↑ calcitriol | Findings of bone resorption:
Preoperative localization of hyperfunctioning parathyroid gland:
Predicting post-operative success:
|
Secondary hyperparathyroidism | Increase in secretion of parathyroid hormone (PTH) from a secondary process. Parathyroid hormone causes increase in serum calcium after long periods. |
|
↑ | ↓/Normal | ↑ | -- | ||
Tertiary hyperparathyroidism | Continuous elevation of parathyroid hormone (PTH) even after successful treatment of the secondary cause of elevated parathyroid hormone. Parathyroid hormone causes increase in serum calcium. |
|
↑ | ↑ | ↑ | -- | ||
Familial hypocalciuric hypercalcemia | This is a genetic disorder caused my mutation in calcium-sensing receptor gene. |
|
Normal/↑ | Normal/↑ | -- | -- |
| |
Malignancy[1][2] | Humoral hypercalcemia of malignancy[3][4][5][6] | Tumor cells secretes parathyroid hormone-related protein (PTHrP) which has similar action as parathyroid hormone. |
|
-- | ↑ | ↓/Normal | ↑ PTHrP
Normal/↑ calcitriol |
|
Osteolytic tumors[7][8] | Multiple myeloma produces osteolysis of bones causing hypercalcemia. Osteolytic metasteses can cause bone resorption causing hypercalcemia. |
|
↓ | ↑ | -- | -- | ||
Production of calcitirol[9] | Some tumors has ectopic activity of 1-alpha-hydroxylase leading to increased production of calcitriol. Calcitriol is active form of vitamin D and causes hypercalcemia. |
|
-- | ↑ | -- | ↑ Calcitriol | ||
Ectopic parathyroid hormone[10] | Some tumors leads to ectopic production of parathyroid hormone. |
|
↑ | ↑ | ↓/Normal | Normal/↑ calcitriol | ||
Medication induced | Lithium[11] | Lithium lowers urinary calcium and causes hypercalcemia. Lithium has been reported to cause an increase in parathyroid hormone and enlargement if parathyroid gland after weeks to months of therapy. |
|
↑ | ↑ | -- | -- |
|
Thiazide diuretics[12] | Thiazide diuretics lowers urinary calcium excretion and causes hypercalcemia. |
|
-- | ↑ | -- | -- | -- | |
Nutritional | Milk-alkali syndrome | Hypercalcemia is be caused by high intake of calcium carbonate. |
|
-- | ↑ | -- | ↓ calcitriol | |
Vitamin D toxicity[13][14][15] | Excess vitamin D causes increased absorption of calcium from intestine causing hypercalcemia. |
|
-- | ↑ | -- | ↑ Vitamin D (calcidiol and/or calcitriol) | -- | |
Granulomatous disease | Sarcoidosis[18] | Hypercalcemia is causes by endogeous production of calcitriol by disease-activated macrophages. |
|
-- | ↑ | -- | ↑ Calcitriol
↑ ACE levels |
DIfferentiating Hyperparathyroidism from other diseases
Disease | Gene | Chromosome | Differentiating Features | Components of MEN | Diagnosis | ||
---|---|---|---|---|---|---|---|
Parathyroid | Pitutary | Pancreas | |||||
von Hippel-Lindau syndrome | Von Hippel–Lindau tumor suppressor | 3p25.3 |
|
- | - | + |
|
Carney complex | PRKAR1A | 17q23-q24 |
|
- | - | - |
|
Neurofibromatosis type 1 | RAS | 17 | - | - | - | Prenatal
Postnatal Cardinal Clinical Features" are required for positive diagnosis.
| |
Li-Fraumeni syndrome | TP53 | 17 | Early onset of diverse amount of cancers such as | - | - | - |
Criteria
|
Gardner's syndrome | APC | 5q21 |
|
- | - | - |
|
Multiple endocrine neoplasia type 2 | RET | - |
|
+ | - | - |
Criteria Two or more specific endocrine tumors
|
Cowden syndrome | PTEN | - | Hamartomas | - | - | - |
|
Acromegaly/gigantism | - | - |
|
- | + | - |
|
Pituitary adenoma | - | - |
|
- | + | - |
|
Hyperparathyroidism | - | - | - | + | - | - |
|
Pheochromocytoma/paraganglioma |
VHL RET NF1 SDHB SDHD |
- | Characterized by | - | - | - |
|
Adrenocortical carcinoma |
|
17p, 13q |
|
- | - | - |
|
Adapted from Toledo SP, Lourenço DM, Toledo RA. A differential diagnosis of inherited endocrine tumors and their tumor counterparts, journal=Clinics (Sao Paulo), volume= 68, issue= 7, 07/24/2013[19] |
References
- ↑ Mirrakhimov AE (2015). "Hypercalcemia of Malignancy: An Update on Pathogenesis and Management". N Am J Med Sci. 7 (11): 483–93. doi:10.4103/1947-2714.170600. PMC 4683803. PMID 26713296.
- ↑ Stewart AF (2005). "Clinical practice. Hypercalcemia associated with cancer". N Engl J Med. 352 (4): 373–9. doi:10.1056/NEJMcp042806. PMID 15673803.
- ↑ Ratcliffe WA, Hutchesson AC, Bundred NJ, Ratcliffe JG (1992). "Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia". Lancet. 339 (8786): 164–7. doi:10.1016/0140-6736(92)90220-W. PMID 1346019.
- ↑ Ikeda K, Ohno H, Hane M, Yokoi H, Okada M, Honma T, Yamada A, Tatsumi Y, Tanaka T, Saitoh T (1994). "Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma". J. Clin. Endocrinol. Metab. 79 (5): 1322–7. doi:10.1210/jcem.79.5.7962324. PMID 7962324.
- ↑ Horwitz MJ, Tedesco MB, Sereika SM, Hollis BW, Garcia-Ocaña A, Stewart AF (2003). "Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers". J. Clin. Endocrinol. Metab. 88 (4): 1603–9. doi:10.1210/jc.2002-020773. PMID 12679445.
- ↑ Stewart AF, Vignery A, Silverglate A, Ravin ND, LiVolsi V, Broadus AE; et al. (1982). "Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity". J Clin Endocrinol Metab. 55 (2): 219–27. doi:10.1210/jcem-55-2-219. PMID 7085851.
- ↑ Roodman GD (2004). "Mechanisms of bone metastasis". N Engl J Med. 350 (16): 1655–64. doi:10.1056/NEJMra030831. PMID 15084698.
- ↑ Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF; et al. (1996). "Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis". J Clin Invest. 98 (7): 1544–9. doi:10.1172/JCI118947. PMC 507586. PMID 8833902.
- ↑ Seymour JF, Gagel RF, Hagemeister FB, Dimopoulos MA, Cabanillas F (1994). "Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma". Ann Intern Med. 121 (9): 633–40. PMID 7944070.
- ↑ VanHouten JN, Yu N, Rimm D, Dotto J, Arnold A, Wysolmerski JJ, Udelsman R (2006). "Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene". J. Clin. Endocrinol. Metab. 91 (2): 580–3. doi:10.1210/jc.2005-2095. PMID 16263810.
- ↑ Mallette LE, Khouri K, Zengotita H, Hollis BW, Malini S (1989). "Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume". J. Clin. Endocrinol. Metab. 68 (3): 654–60. doi:10.1210/jcem-68-3-654. PMID 2918061.
- ↑ Griebeler ML, Kearns AE, Ryu E, Thapa P, Hathcock MA, Melton LJ; et al. (2016). "Thiazide-Associated Hypercalcemia: Incidence and Association With Primary Hyperparathyroidism Over Two Decades". J Clin Endocrinol Metab. 101 (3): 1166–73. doi:10.1210/jc.2015-3964. PMC 4803175. PMID 26751196.
- ↑ Hoeck HC, Laurberg G, Laurberg P (1994). "Hypercalcaemic crisis after excessive topical use of a vitamin D derivative". J. Intern. Med. 235 (3): 281–2. PMID 8120527.
- ↑ Jacobus CH, Holick MF, Shao Q, Chen TC, Holm IA, Kolodny JM, Fuleihan GE, Seely EW (1992). "Hypervitaminosis D associated with drinking milk". N. Engl. J. Med. 326 (18): 1173–7. doi:10.1056/NEJM199204303261801. PMID 1313547.
- ↑ Sharma OP (1996). "Vitamin D, calcium, and sarcoidosis". Chest. 109 (2): 535–9. PMID 8620732.
- ↑ Jacobus CH, Holick MF, Shao Q, Chen TC, Holm IA, Kolodny JM, Fuleihan GE, Seely EW (1992). "Hypervitaminosis D associated with drinking milk". N. Engl. J. Med. 326 (18): 1173–7. doi:10.1056/NEJM199204303261801. PMID 1313547.
- ↑ Hoeck HC, Laurberg G, Laurberg P (1994). "Hypercalcaemic crisis after excessive topical use of a vitamin D derivative". J. Intern. Med. 235 (3): 281–2. PMID 8120527.
- ↑ Dusso AS, Kamimura S, Gallieni M, Zhong M, Negrea L, Shapiro S, Slatopolsky E (1997). "gamma-Interferon-induced resistance to 1,25-(OH)2 D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses". J. Clin. Endocrinol. Metab. 82 (7): 2222–32. doi:10.1210/jcem.82.7.4074. PMID 9215298.
- ↑ Toledo SP, Lourenço DM, Toledo RA (2013). "A differential diagnosis of inherited endocrine tumors and their tumor counterparts". Clinics (Sao Paulo). 68 (7): 1039–56. doi:10.6061/clinics/2013(07)24. PMC 3715026. PMID 23917672.